|
PAQR3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6153745008296E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.91433543964104E-13 |
| Normal-vs-Stage2 |
2.7725599593964E-12 |
| Normal-vs-Stage3 |
1.92468263549017E-12 |
| Normal-vs-Stage4 |
1.98374650040023E-12 |
| Stage1-vs-Stage2 |
3.816000E-01 |
| Stage1-vs-Stage3 |
7.033800E-01 |
| Stage1-vs-Stage4 |
4.964800E-01 |
| Stage2-vs-Stage3 |
5.939600E-01 |
| Stage2-vs-Stage4 |
8.705400E-01 |
| Stage3-vs-Stage4 |
7.265600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62203583897735E-13 |
| Normal-vs-AfricanAmerican |
1.33800000001738E-06 |
| Normal-vs-Asian |
8.73190408867686E-13 |
| Caucasian-vs-AfricanAmerican |
3.488200E-01 |
| Caucasian-vs-Asian |
4.292200E-01 |
| AfricanAmerican-vs-Asian |
1.984770E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.90798504668055E-14 |
| Normal-vs-Female |
3.76032538440541E-13 |
| Male-vs-Female |
2.106000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.20889972979421E-12 |
| Normal-vs-Age(41-60Yrs) |
1.22124532708767E-14 |
| Normal-vs-Age(61-80Yrs) |
2.03292938039112E-12 |
| Normal-vs-Age(81-100Yrs) |
1.618390E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.907900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.026000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.848640E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.621600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.418100E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.603800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.208400E-01 |
| Classical-VS-Follicular |
6.251700E-02 |
| Classical-VS-Other |
5.727400E-01 |
| Classical-VS-Normal |
8.27204971187712E-12 |
| Tall-VS-Follicular |
3.270400E-01 |
| Tall-VS-Other |
6.177600E-01 |
| Tall-VS-Normal |
1.08400000087272E-09 |
| Follicular-VS-Other |
9.525000E-01 |
| Follicular-VS-Normal |
1.87849735766576E-12 |
| Other-VS-Normal |
6.809800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63535851527286E-12 |
| Normal-vs-N1 |
1.89093185554157E-12 |
| N0-vs-N1 |
8.860600E-01 |
|
|
